Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(9), P. 2990 - 2990
Published: April 25, 2025
Lipoprotein(a)
[Lp(a)]
has
attracted
widespread
interest
as
a
potential
biomarker
for
cerebrovascular
diseases
due
to
its
genetically
determined
and
stable
plasma
concentration
throughout
life.
Lp(a)
exhibits
pro-atherogenic
pro-thrombotic
properties
that
contribute
vascular
pathology
in
both
extracranial
intracranial
vessels.
Elevated
levels
are
strongly
associated
with
large-artery
atherosclerotic
stroke,
while
data
on
role
other
ischemic
subtypes
hemorrhagic
stroke
remains
limited
inconsistent.
Recent
advances
Lp(a)-lowering
therapies,
such
antisense
oligonucleotides
RNA-based
agents,
have
demonstrated
significant
efficacy
reducing
levels.
These
prompted
increasing
research
into
their
application
the
prevention
treatment
of
diseases,
aiming
determine
whether
reduction
may
translate
reduced
risk
atherosclerosis.
This
narrative
review
summarizes
current
evidence
association
between
focusing
utility
patient
stratification.
It
also
highlights
existing
knowledge
gaps
outlines
directions
future
research,
particularly
understanding
subtype-specific
effects
evaluating
clinical
benefits
Lp(a)-targeted
therapies.
Frontiers in Cardiovascular Medicine,
Journal Year:
2025,
Volume and Issue:
12
Published: April 24, 2025
Introduction
We
aimed
to
assess
the
usefulness
of
lipoprotein(a)
[Lp(a)]
and
LDL-C
levels
as
potential
predictors
coronary
lesions'
complexity
in
patients
with
premature
artery
disease
(pCAD).
Methods
This
study
enrolled
162
consecutive
pCAD
undergoing
angiography.
The
SYNTAX
score
(SS)
was
used
complexity.
Linear
discriminant
analysis
(LDA)
employed
construct
a
multivariate
classification
model
enabling
prediction
SS.
Results
Lp(a)
among
SS
≥
23
1-22
were
significantly
higher
than
those
=
0
(
p
0.021
0.027,
respectively).
cut-off
point
for
level
63.5
mg/dl
discriminated
subjects
from
≤
22
(sensitivity
0.546,
specificity
0.780;
AUC
0.620;
0.027).
An
LDA-based
involving
level,
age,
sex
provided
improved
discrimination
performance
0.727,
0.733,
0.800;
0.0001).
Conclusions
are
associated
advancement
lesions
patients.
can
be
identification
23.
modelling
using
Lp(a),
LDL-C,
age
gender
may
an
applicable
tool
preliminary
at
risk
more
complex
lesions.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(9), P. 2990 - 2990
Published: April 25, 2025
Lipoprotein(a)
[Lp(a)]
has
attracted
widespread
interest
as
a
potential
biomarker
for
cerebrovascular
diseases
due
to
its
genetically
determined
and
stable
plasma
concentration
throughout
life.
Lp(a)
exhibits
pro-atherogenic
pro-thrombotic
properties
that
contribute
vascular
pathology
in
both
extracranial
intracranial
vessels.
Elevated
levels
are
strongly
associated
with
large-artery
atherosclerotic
stroke,
while
data
on
role
other
ischemic
subtypes
hemorrhagic
stroke
remains
limited
inconsistent.
Recent
advances
Lp(a)-lowering
therapies,
such
antisense
oligonucleotides
RNA-based
agents,
have
demonstrated
significant
efficacy
reducing
levels.
These
prompted
increasing
research
into
their
application
the
prevention
treatment
of
diseases,
aiming
determine
whether
reduction
may
translate
reduced
risk
atherosclerosis.
This
narrative
review
summarizes
current
evidence
association
between
focusing
utility
patient
stratification.
It
also
highlights
existing
knowledge
gaps
outlines
directions
future
research,
particularly
understanding
subtype-specific
effects
evaluating
clinical
benefits
Lp(a)-targeted
therapies.
